
    
      This was a phase III, multicentre, prospective, open label, repeat treatment cycles,
      extension to the double study Y-52-52120-145 (Study 145) . The study included both rollover
      subjects from Study 145 and de novo subjects. The primary study objective was to assess the
      long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke
      or traumatic brain injury over repeated treatment cycles. The secondary study objective was
      to assess the long term efficacy of repeated treatment with Dysport®.
    
  